Compare INTT & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INTT | SKYE |
|---|---|---|
| Founded | 1981 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.2M | 9.0M |
| IPO Year | 1997 | 2013 |
| Metric | INTT | SKYE |
|---|---|---|
| Price | $10.71 | $1.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $13.50 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 94.9K | 81.7K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $66,801,000.00 | N/A |
| Revenue This Year | $15.82 | N/A |
| Revenue Next Year | $9.10 | N/A |
| P/E Ratio | $179.42 | ★ N/A |
| Revenue Growth | ★ 66.06 | N/A |
| 52 Week Low | $7.07 | $0.26 |
| 52 Week High | $20.00 | $4.99 |
| Indicator | INTT | SKYE |
|---|---|---|
| Relative Strength Index (RSI) | 35.57 | 55.17 |
| Support Level | $10.32 | $1.64 |
| Resistance Level | $10.88 | $2.28 |
| Average True Range (ATR) | 0.48 | 0.22 |
| MACD | 0.04 | -0.06 |
| Stochastic Oscillator | 7.28 | 32.67 |
inTest Corp is a supplier of test and process technology solutions for use in manufacturing and testing across a wide range of markets, including Semi, Auto/EV, Defense/Aerospace, Industrial, Life Sciences, Safety/Security, and Other. The Company has three operating segments, which are also its reportable segments and reporting units: Electronic Test, which generates the majority of its revenue and includes semiconductor test equipment, flying probe, and in-circuit testers; Environmental Technologies, which includes thermal test, process, and storage products; and Process Technologies, which includes induction heating and video imaging products. The Company generates the maximum revenue from the U.S.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.